Replimune Group, Inc.

For the period ended Dec 31, 2024. Filed Feb 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 12, 2025

REPL$22.26+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Amounts in thousands, except share and per share amounts)

	Three Months Ended December 31,		Nine Months Ended December 31,
	2024	2023	2024	2023
Operating expenses:
Research and development	$48,004	$42,847	$135,472	$132,384
Selling, general and administrative	18,015	13,693	46,827	43,633
Total operating expenses	66,019	56,540	182,299	176,017
Loss from operations	(66,019)	(56,540)	(182,299)	(176,017)
Other income (expense):
Research and development incentives	376	415	1,222	1,251
Investment income	5,137	5,686	15,243	17,922
Interest expense on finance lease liability	(528)	(540)	(1,594)	(1,626)
Interest expense on debt obligations	(1,450)	(1,012)	(4,314)	(3,083)
Other (expense) income	(3,281)	1,344	(850)	1,307
Total other income (expense), net	254	5,893	9,707	15,771
Loss before income taxes	$(65,765)	$(50,647)	$(172,592)	$(160,246)
Income tax provision	575	$473	$575	$473
Net loss	$(66,340)	$(51,120)	$(173,167)	$(160,719)
Net loss per common share, basic and diluted	$(0.79)	$(0.77)	$(2.25)	$(2.42)
Weighted average common shares outstanding, basic and diluted	83,498,892	66,645,691	77,113,695	66,532,488

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.